Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PPP1R15A_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PPP1R15A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PPP1R15A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPP1R15A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PPP1R15A_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPP1R15A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PPP1R15A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PPP1R15A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PPP1R15A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PPP1R15A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPP1R15A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007026211 | Oral cavity | EOLP | peptidyl-serine dephosphorylation | 11/2218 | 19/18723 | 1.91e-06 | 4.41e-05 | 11 |
GO:000644624 | Oral cavity | EOLP | regulation of translational initiation | 25/2218 | 79/18723 | 2.47e-06 | 5.50e-05 | 25 |
GO:001092114 | Oral cavity | EOLP | regulation of phosphatase activity | 25/2218 | 84/18723 | 8.43e-06 | 1.61e-04 | 25 |
GO:007097223 | Oral cavity | EOLP | protein localization to endoplasmic reticulum | 22/2218 | 74/18723 | 2.93e-05 | 4.23e-04 | 22 |
GO:003530712 | Oral cavity | EOLP | positive regulation of protein dephosphorylation | 16/2218 | 45/18723 | 3.15e-05 | 4.46e-04 | 16 |
GO:00325164 | Oral cavity | EOLP | positive regulation of phosphoprotein phosphatase activity | 10/2218 | 21/18723 | 5.45e-05 | 7.01e-04 | 10 |
GO:007005923 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 19/2218 | 63/18723 | 8.12e-05 | 9.69e-04 | 19 |
GO:190010121 | Oral cavity | EOLP | regulation of endoplasmic reticulum unfolded protein response | 12/2218 | 30/18723 | 8.20e-05 | 9.77e-04 | 12 |
GO:003096822 | Oral cavity | EOLP | endoplasmic reticulum unfolded protein response | 21/2218 | 74/18723 | 9.37e-05 | 1.09e-03 | 21 |
GO:190357324 | Oral cavity | EOLP | negative regulation of response to endoplasmic reticulum stress | 15/2218 | 44/18723 | 9.66e-05 | 1.12e-03 | 15 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
GO:003530612 | Oral cavity | EOLP | positive regulation of dephosphorylation | 18/2218 | 59/18723 | 1.05e-04 | 1.19e-03 | 18 |
GO:190589724 | Oral cavity | EOLP | regulation of response to endoplasmic reticulum stress | 22/2218 | 82/18723 | 1.60e-04 | 1.69e-03 | 22 |
GO:000698422 | Oral cavity | EOLP | ER-nucleus signaling pathway | 15/2218 | 46/18723 | 1.71e-04 | 1.78e-03 | 15 |
GO:004355521 | Oral cavity | EOLP | regulation of translation in response to stress | 9/2218 | 20/18723 | 2.23e-04 | 2.21e-03 | 9 |
GO:003649021 | Oral cavity | EOLP | regulation of translation in response to endoplasmic reticulum stress | 6/2218 | 11/18723 | 7.46e-04 | 6.03e-03 | 6 |
GO:190389721 | Oral cavity | EOLP | regulation of PERK-mediated unfolded protein response | 6/2218 | 11/18723 | 7.46e-04 | 6.03e-03 | 6 |
GO:00109225 | Oral cavity | EOLP | positive regulation of phosphatase activity | 11/2218 | 34/18723 | 1.34e-03 | 9.33e-03 | 11 |
GO:003530815 | Oral cavity | EOLP | negative regulation of protein dephosphorylation | 11/2218 | 34/18723 | 1.34e-03 | 9.33e-03 | 11 |
GO:014046721 | Oral cavity | EOLP | integrated stress response signaling | 8/2218 | 22/18723 | 2.64e-03 | 1.59e-02 | 8 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414118 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0414119 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0414124 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
hsa0414134 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
hsa0414143 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
hsa0414153 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0414125 | Cervix | HSIL_HPV | Protein processing in endoplasmic reticulum | 21/459 | 174/8465 | 4.54e-04 | 3.80e-03 | 3.07e-03 | 21 |
hsa0414135 | Cervix | HSIL_HPV | Protein processing in endoplasmic reticulum | 21/459 | 174/8465 | 4.54e-04 | 3.80e-03 | 3.07e-03 | 21 |
hsa0414126 | Endometrium | AEH | Protein processing in endoplasmic reticulum | 62/1197 | 174/8465 | 5.97e-13 | 1.39e-11 | 1.01e-11 | 62 |
hsa04141111 | Endometrium | AEH | Protein processing in endoplasmic reticulum | 62/1197 | 174/8465 | 5.97e-13 | 1.39e-11 | 1.01e-11 | 62 |
hsa0414127 | Endometrium | EEC | Protein processing in endoplasmic reticulum | 64/1237 | 174/8465 | 2.17e-13 | 5.09e-12 | 3.80e-12 | 64 |
hsa0414136 | Endometrium | EEC | Protein processing in endoplasmic reticulum | 64/1237 | 174/8465 | 2.17e-13 | 5.09e-12 | 3.80e-12 | 64 |
hsa0414139 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
hsa04141114 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa0414114 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
hsa0414115 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP1R15A | SNV | Missense_Mutation | novel | c.682N>A | p.Glu228Lys | p.E228K | O75807 | protein_coding | deleterious(0.03) | probably_damaging(0.914) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
PPP1R15A | SNV | Missense_Mutation | novel | c.776N>T | p.Ser259Phe | p.S259F | O75807 | protein_coding | deleterious(0) | benign(0.087) | TCGA-GM-A2DF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
PPP1R15A | insertion | Nonsense_Mutation | novel | c.2017_2018insATAATGAATAAATAAATAAATAAATA | p.Arg673HisfsTer4 | p.R673Hfs*4 | O75807 | protein_coding | | | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PPP1R15A | deletion | Frame_Shift_Del | rs764798313 | c.996delN | p.Pro334HisfsTer6 | p.P334Hfs*6 | O75807 | protein_coding | | | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15A | deletion | Frame_Shift_Del | | c.1977_1992delNNNNNNNNNNNNNNNN | p.Ser660LeufsTer26 | p.S660Lfs*26 | O75807 | protein_coding | | | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
PPP1R15A | SNV | Missense_Mutation | novel | c.545C>T | p.Ser182Leu | p.S182L | O75807 | protein_coding | deleterious(0.03) | possibly_damaging(0.588) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PPP1R15A | SNV | Missense_Mutation | | c.1412C>T | p.Ser471Phe | p.S471F | O75807 | protein_coding | deleterious(0.04) | benign(0.038) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
PPP1R15A | SNV | Missense_Mutation | | c.403N>A | p.Ala135Thr | p.A135T | O75807 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PPP1R15A | SNV | Missense_Mutation | novel | c.849N>T | p.Glu283Asp | p.E283D | O75807 | protein_coding | tolerated(0.42) | benign(0.003) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15A | SNV | Missense_Mutation | | c.697G>A | p.Glu233Lys | p.E233K | O75807 | protein_coding | tolerated(0.06) | possibly_damaging(0.876) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |